No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 21 of the 40 quarters in the window, leaving 19 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 13.8x · 10Y median 16.1x · 48th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T15:57:17.755Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Marker Therapeutics, Inc. (MRKR) stock was $1.02 as of Oct 6, 2026, 11:51 AM EDT, down 3.77% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +11.1% · 3-year avg -33.5%/yr · 5-year avg -42.1%/yr
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines.
Biotechnology · Houston, TX
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.12
Revenue Est.
$2.12M
Last Quarter Results
EPS
$-0.09
vs Estimate
$-0.18
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MRKR | $17.01M | $1.02 | -3.77% | +11.06% | -42.13% | -33.25% | N/A |
| 2PAVM | $16.92M | $2.65 | -0.38% | -79.49% | -76.55% | -54.03% | vs MRKR |
| 3LPCN | $17.19M | $2.08 | +0.72% | -38.07% | -34.76% | -29.99% | vs MRKR |
| 4PTN | $16.73M | $9.40 | -0.84% | +20.66% | -55.41% | -35.08% | vs MRKR |
| 5BNGO | $16.64M | $1.45 | +0.35% | -24.38% | -78.37% | N/A | vs MRKR |
| 6COSM | $17.48M | $0.32 | -7.09% | -67.82% | -68.41% | -45.52% | vs MRKR |
forward FY estimate
N/A
$700000.00
vs Estimate
$660667.00
Consensus Rating
Based on 3 analysts
Average Price Target
$7.87
+671.2% upside
Low
$5.60
Current
$1.02
High
$10.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.16 | $-0.12 | $-0.07 | 2 |
| Quarter ending Dec 2026 | $-0.26 | $-0.22 | $-0.18 | 2 |
| Quarter ending Mar 2027 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Quarter ending Jun 2027 | $-0.25 | $-0.25 | $-0.25 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.60 | $-0.59 | $-0.58 | 2 |
| FY 2027 | $-1.12 | $-0.88 | $-0.63 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $604380.00 | $2.12M | $3.63M | 2 |
| Quarter ending Dec 2026 | $715333.00 | $715333.00 | $715333.00 | 2 |
| Quarter ending Mar 2027 | $1.20M | $1.20M | $1.20M | 1 |
| Quarter ending Jun 2027 | $1.20M | $1.20M | $1.20M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $2.83M | $4.24M | $5.66M | 2 |
| FY 2027 | $6.85M | $20.19M | $33.52M | 2 |
